Related Experiment Video
Updated: May 10, 2025
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Novel Therapeutics for Familial Chylomicronemia Syndrome
Maria Cristina Izar1,2, Francisco Antonio Helfenstein Fonseca3
1Cardiology Division, Department of Medicine, Universidade Federal de São Paulo (UNIFESP), Rua José de Magalhães, São Paulo, SP, 34004026 - 090, Brazil. mcoizar@terra.com.br.
Purpose Of Review:
This review discusses new treatment approaches for familial chylomicronemia syndrome (FCS), a rare disorder affecting triglyceride metabolism. The focus is on antisense oligonucleotides (ASO) and small-interfering RNA (siRNA) therapies targeting APOC3 and angiopoietin-like protein 3 (ANGPTL3).
Recent Findings:
Volanesorsen, an ASO targeting APOC3, has shown effectiveness in managing FCS, multifactorial chylomicronemia, and familial partial lipodystrophy, but its use is limited by thrombocytopenia. Emerging therapies, Olezarsen (ASO anti-APOC3) and Plozasiran (siRNA anti-APOC3), both conjugated with GalNAc, show promise in reducing acute pancreatitis risk without platelet concerns. ANGPTL3 inhibition requires residual lipoprotein lipase (LPL) activity, with only siRNA-based therapies-zodasiran and solbinsiran-under investigation. Suppressing APOC3 expression and targeting ANGPTL3 via siRNA offer significant potential, but long-term studies are needed to confirm their efficacy and safety. Future research may explore gene-editing strategies using lipid nanoparticle-based CRISPR-Cas9 delivery for more durable treatment outcomes.
Insights
New antisense oligonucleotide (ASO) and small-interfering RNA (siRNA) therapies show promise for familial chylomicronemia syndrome (FCS). These treatments target APOC3 and ANGPTL3, offering potential benefits with fewer side effects than current options.
Area of Science:
- Genetics and Molecular Biology
- Metabolic Disorders
- Pharmacology
Background:
- Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by severe hypertriglyceridemia.
- Current management of FCS is limited, necessitating novel therapeutic strategies.
- Triglyceride metabolism is intricately regulated by proteins such as APOC3 and ANGPTL3.
Purpose of the Study:
- To review emerging therapeutic approaches for familial chylomicronemia syndrome (FCS).
- To focus on antisense oligonucleotides (ASO) and small-interfering RNA (siRNA) targeting APOC3 and ANGPTL3.
- To evaluate the efficacy and safety of these novel treatments.
Main Methods:
- Review of current literature on ASO and siRNA therapies for FCS.
- Analysis of clinical trial data for agents targeting APOC3 and ANGPTL3.
- Exploration of potential future gene-editing strategies.
Main Results:
- Volanesorsen (ASO anti-APOC3) demonstrated efficacy but was associated with thrombocytopenia.
- Emerging therapies Olezarsen (ASO anti-APOC3) and Plozasiran (siRNA anti-APOC3) show promise for reducing pancreatitis risk without platelet issues.
- ANGPTL3 inhibition via siRNA (zodasiran, solbinsiran) is under investigation and requires residual LPL activity.
Conclusions:
- ASO and siRNA therapies targeting APOC3 and ANGPTL3 represent significant advancements in FCS treatment.
- Further long-term studies are essential to confirm the safety and efficacy of these novel agents.
- Gene-editing technologies may offer durable treatment solutions for FCS in the future.
